IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL att erhålla royalties. Avtalet har formellt undertecknats av Immunotech, ett dotterbolag till Beckman Coulter.
Läs pressmeddelandet här.
A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...
Last week, IDL Diagnostics participated in the Sweden-Indonesia Sustainability Partnership (SISP) 2025, organized by Business Sweden and the Swedish Embassy in Indonesia. The Sweden-Indonesia Sustainability Partnership (SISP) is a platform designed to foster...
